258 related articles for article (PubMed ID: 29978156)
41. A Case of Euglycemic Diabetic Ketoacidosis (DKA), Influenza, and a Dipeptidyl Peptidase-4 (DPP-4) Inhibitor.
Jeong SH; Vorachitti M; Fuentes F
Cureus; 2023 May; 15(5):e39012. PubMed ID: 37378199
[TBL] [Abstract][Full Text] [Related]
42. [Euglycemic Diabetic Ketoacidosis Caused by a Sodium-glucose Co-transporter (SGLT) 2 Inhibitor after Coronary Artery Bypass Grafting].
Kameda Y; Kato M; Inoue B; Yamazaki S; Sahara N; Aoki T; Nagashima Y; Nemoto N; Anzai H; Araki W; Kobayashi N
Kyobu Geka; 2019 May; 72(5):354-357. PubMed ID: 31268032
[TBL] [Abstract][Full Text] [Related]
43. EUGLYCEMIC DIABETIC KETOACIDOSIS AND SEVERE ACUTE KIDNEY INJURY SECONDARY TO OFF LABEL USE OF SODIUM GLUCOSE COTRANSPORTER-2 INHIBITOR IN A TYPE-1 DIABETIC PATIENT.
Tahir H; Wani A; Daruwalla V; Daboul N; Sagi J
J Ayub Med Coll Abbottabad; 2015; 27(4):923-4. PubMed ID: 27004352
[TBL] [Abstract][Full Text] [Related]
44. Prediabetes Directly Deteriorates into Diabetic Ketoacidosis and Hyperosmolar Hyperglycemic Syndrome Triggered by Acute Pancreatitis: A Case Report Illustrating a "Chicken and Egg" Paradigm in Ketosis-Prone Diabetes.
Song R; Cao S
Diabetes Ther; 2018 Jun; 9(3):1377-1383. PubMed ID: 29600506
[TBL] [Abstract][Full Text] [Related]
45. Misleading Presentation: Chest Pain Masking Euglycemic Diabetic Ketoacidosis Possibly Induced by Empagliflozin.
Tiwari K; Sharma NR; Pokhrel M; Basnet A; Kaplan M
Cureus; 2023 Nov; 15(11):e49402. PubMed ID: 38149142
[TBL] [Abstract][Full Text] [Related]
46. Management of Diabetic Ketoacidosis in Adults: A Narrative Review.
Eledrisi MS; Elzouki AN
Saudi J Med Med Sci; 2020; 8(3):165-173. PubMed ID: 32952507
[TBL] [Abstract][Full Text] [Related]
47. Euglycaemic diabetic ketoacidosis in a patient with type 2 diabetes started on empagliflozin.
Rashid O; Farooq S; Kiran Z; Islam N
BMJ Case Rep; 2016 May; 2016():. PubMed ID: 27177938
[TBL] [Abstract][Full Text] [Related]
48. Sodium-glucose Cotransporter 2 Inhibitors and the Risk of Diabetic Ketoacidosis; from Pathophysiology to Clinical Practice.
Patoulias D; Manafis A; Mitas C; Avranas K; Lales G; Zografou I; Sambanis C; Karagiannis A
Cardiovasc Hematol Disord Drug Targets; 2018; 18(2):139-146. PubMed ID: 29412120
[TBL] [Abstract][Full Text] [Related]
49. Sodium-Glucose Linked Transporter Inhibitors as a Cause of Euglycemic Diabetic Ketoacidosis on a Background of Starvation.
Tauseef A; Asghar MS; Zafar M; Lateef N; Thirumalareddy J
Cureus; 2020 Aug; 12(8):e10078. PubMed ID: 33005504
[TBL] [Abstract][Full Text] [Related]
50. Dengue hemorrhagic fever grade III with diabetic ketoacidosis: a case report.
Supradish PO; Rienmanee N; Fuengfoo A; Kalayanarooj S
J Med Assoc Thai; 2011 Aug; 94 Suppl 3():S233-40. PubMed ID: 22043783
[TBL] [Abstract][Full Text] [Related]
51. Diabetic ketoacidosis and acute mountain sickness: case report and review of treatment options in type 1 diabetes mellitus.
Miller SC
Wilderness Environ Med; 2015 Jun; 26(2):185-8. PubMed ID: 25899916
[TBL] [Abstract][Full Text] [Related]
52. [Sodium-glucose-cotransporter 2 inhibitor-associated euglycaemic diabetic ketoacidosis].
Fisker F; Møller N; Lauritzen ES
Ugeskr Laeger; 2019 May; 181(21):. PubMed ID: 31124439
[TBL] [Abstract][Full Text] [Related]
53. A Case of Euglycemic Diabetic Ketoacidosis in a Patient With Type 2 Diabetes Mellitus and COVID-19.
Morrison N; Barnett K; Tantum J; Morrison HK; Whalen M
Cureus; 2020 Dec; 12(12):e12029. PubMed ID: 33457131
[TBL] [Abstract][Full Text] [Related]
54. Euglycemic Diabetic Ketoacidosis in Concurrent Very Low-carbohydrate Diet and Sodium-glucose Transporter-2 Inhibitor Use: A Case Report.
Earle M; Ault B; Bonney C
Clin Pract Cases Emerg Med; 2020 May; 4(2):185-188. PubMed ID: 32426668
[TBL] [Abstract][Full Text] [Related]
55. Differences in metabolic and hormonal milieu in diabetic- and alcohol-induced ketoacidosis.
Umpierrez GE; DiGirolamo M; Tuvlin JA; Isaacs SD; Bhoola SM; Kokko JP
J Crit Care; 2000 Jun; 15(2):52-9. PubMed ID: 10877365
[TBL] [Abstract][Full Text] [Related]
56. Diabetic ketoacidosis: risk factors and management strategies.
Umpierrez GE; Kitabchi AE
Treat Endocrinol; 2003; 2(2):95-108. PubMed ID: 15871546
[TBL] [Abstract][Full Text] [Related]
57. Euglycemic Diabetic Ketoacidosis, a Misleading Presentation of Diabetic Ketoacidosis.
Thawabi M; Studyvin S
N Am J Med Sci; 2015 Jun; 7(6):291-4. PubMed ID: 26199928
[TBL] [Abstract][Full Text] [Related]
58. Euglycemic Diabetic Ketoacidosis With Sodium-Glucose Cotransporter-2 Inhibitor Use Post-Bariatric Surgery: A Brief Review of the Literature.
Iqbal QZ; Mishiyev D; Zia Z; Ruggiero RA; Aftab G
Cureus; 2020 Oct; 12(10):e10878. PubMed ID: 33178530
[TBL] [Abstract][Full Text] [Related]
59. Euglycaemic DKA secondary to Canaglifozin, an easily missed diagnosis.
Bhatnagar RK; Kurera I; Perry R; Tringham J
Acute Med; 2017; 16(4):196-199. PubMed ID: 29300799
[TBL] [Abstract][Full Text] [Related]
60. Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence.
Scheen AJ; Paquot N
Diabetes Metab; 2014 Dec; 40(6 Suppl 1):S4-S11. PubMed ID: 25554070
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
